Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-07-24
2007-07-24
O'Hara, Eileen B. (Department: 1646)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S069100, C435S320100, C435S325000, C435S252300, C536S023500, C530S399000
Reexamination Certificate
active
10998425
ABSTRACT:
The present invention relates to a keratinocyte growth factor fragment, KGFdes1-23, or an analog thereof that is composed of a portion of an amino acid sequence of mature, full length keratinocyte growth factor, KGF163. The fragment exhibits at least a 2-fold increase in mitogenic activity as compared to a mature, recombinant keratinocyte growth factor, rKGF, but lacks a sequence comprising the first 23 amino acid residues, C-N-D-M-T-P-E-Q-M-A-T-N-V-N-C-S-S-P-E-R-H-T-R- (SEQ ID NO: 2) of the KGF163N-terminus. The present invention also relates to a DNA molecule encoding KGFdes1-23, an expression vector and a transformed host containing the DNA molecule, and a method of producing KGFdes1-23by culturing the transformed host. The present invention further relates to a conjugate of KGFdes1-23and a toxin molecule, and the use thereof for treatment of hyperproliferative disease of the epidermis. Moreover, the present invention relates to a therapeutic composition containing KGFdes1-23and a pharmaceutically acceptable carrier and the use thereof for wound healing purposes.
REFERENCES:
patent: 5654405 (1997-08-01), Rubin et al.
patent: 5665870 (1997-09-01), Rubin et al.
patent: 5677278 (1997-10-01), Gospodarowicz et al.
patent: 5707805 (1998-01-01), Rubin et al.
patent: 5731170 (1998-03-01), Rubin et al.
patent: 5741642 (1998-04-01), Rubin et al.
patent: 5773586 (1998-06-01), Gospodarowicz et al.
patent: 5814605 (1998-09-01), Pierce et al.
patent: 5824643 (1998-10-01), Pierce et al.
patent: 5843883 (1998-12-01), Gospodarowicz et al.
patent: 5863767 (1999-01-01), Gospodarowicz et al.
patent: 5965530 (1999-10-01), Pierce et al.
patent: 6074848 (2000-06-01), Gospodarowicz et al.
patent: 6420531 (2002-07-01), Rubin et al.
patent: PCT WO 90/08771 (1990-08-01), None
patent: PCT WO 96/11949 (1996-04-01), None
patent: PCT WO 96/11951 (1996-04-01), None
Ron et al., J. Biol. Chem., 1993, vol. 268(4), pp. 2984-2988.
Bare et al., 1994, Biochem. Biophys. Res. Commun. 205:872-879.
Ornitz and Itoh, 2001, Genome Biology, vol. 2(3), pp. 1-12.
Osslund et al., Protein Sci., 1998, 7:1681-1690.
Bellosta et al.,J. Cell Biol. 121(3):705-713 (1993).
Baird et al., “Receptor-and Heparin-Binding Domains of Basic Fibroblast Growth Factor,”Proc. Natl. Acad. Sci. U.S.A. 85:2324-2328 (1988).
Bowie et al.Science 247:1306-1310 (1990).
Burgess and Maciag, “The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins,”Anan. Rev. Biochem. 58:575-605 (1989).
Curti., Crit. Rev. Oncology/Hematology 14:29-39 (1993).
Eriksson et al., “Three-Dimensional Structure of Human Basic Fibroblast Growth Factor,”Proc. Natl. Acad. Sci. U.S.A. 88:3441-3445 (1991).
Finch et al.,Science 2:752-755 (1989).
Gospodarowicz et al., “Comparison of the Ability of Basic and Acidic Fibroblast Growth Factor to Stimulate the Proliferation of an Established Keratinocyte Cell Line: Modulation of Their Biological Effects by Heparin, Transforming Growth Factor β (TGFβ), and Epidermal Growth Factor (EGF),”Journal of Cellular Physiology 142:325-333 (1990).
Harper and Lobb, “Reductive Methylation of Lysine Residues in Acidic Fibroblast Growth Factor: Effect on Mitogenic Activity and Heparin Affinity,”Biochemistry 27:671-678 (1988).
Jain., Sci. Amer. 271:58-65 (1994).
Meyer-Ingold., TibTech 11:387-392 (1993).
Nybo et al., Letter to the Editor “Mitogenic Activity of Keratinocyte Growth Factor Amino-Terminal Truncation Mutants: Delection of Amino Acid Residues 1-15 Through 1-27”, In Vitro Cell Dev. Biol., Animal 33:606-607 (1997).
Osslund et al., “Correlation Between the 1.6 Å Crystal Structure and Mutational Analysis of Keratinocyte Growth Factor,”Protein Science 7:1681-1690 (1998).
Reich-Slotky et al., “Chimeric Molecules Between Keratinocyte Growth Factor and Basic Fibroblast Growth Factor Define Domains That Confer Receptor Binding Specificities,”The Journal of Biological Chemistry 270(50):29813-29818 (1995).
Robinson, TibTech 10:1-2 (1992).
Ron et al.J. Biol Chem. 268(4):2984-2988.
Rubin et al., “Purification and Characterization of a Newly Identified Growth Factor Specific for Epithelial Cells”, Proc. Natl. Acad. Sci. USA, 86:802-806 (1989).
Gospodarowicz Denis J.
Masiarz Frank R.
Chiron Corporation
Harbin Alisa A.
O'Hara Eileen B.
Robins Roberta
Xie Xiaozhen
LandOfFree
Truncated keratinocyte growth factor (KGF) having increased... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Truncated keratinocyte growth factor (KGF) having increased..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Truncated keratinocyte growth factor (KGF) having increased... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3809094